▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1857 by analyst upside · 2026-11-12
AFYA
Afya Limited
Consumer Defensive · Market Cap $949M · P/E 6.5x
ANALYST PRICE TARGET
+39.5%
implied upside to consensus target
Current Price $10.73
Consensus Target $14.97
Bull Target $17.05
Bear Target $11.69
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
3
Hold
3
Sell
0
52-Week Low $9.66
52-Week High $16.16
YTD Return -25.1%
FUNDAMENTALS
Market Cap $949M
P/E Ratio (TTM) 6.5x
Forward P/E 5.3x
EPS (TTM) $1.64
PEG Ratio N/A
Dividend Yield 6.25%
Revenue (TTM) $3.8B
Profit Margin 20.4%
52-WEEK RANGE
52-Week Low $9.66
52-Week High $16.16
Current Price $10.73
Bear Target $11.69
Bull Target $17.05
● Now $10.73 ● Target $14.97
TRADING DATA
Avg Volume 398K
YTD Return -25.1%
Analyst Count 8
Consensus Buy
Upside to Target +39.5%
Last Updated 2026-11-12

ANALYST SUMMARY

Afya Limited (AFYA) is currently trading at $10.73 with a Wall Street consensus price target of $14.97, implying potential upside of 39.5% over the next 12 months. 8 analysts currently cover AFYA, with a consensus rating of Buy - 62% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $17.05, while the most cautious has a target of $11.69.

AFYA operates in the Consumer Defensive sector with a market capitalisation of $949M. The stock is down 25.1% year-to-date and is currently trading near the lower end of its 52-week range of $9.66 – $16.16.

SIMILAR STOCKS

Other Consumer Defensive stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for AFYA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan - Reiterated
Overweight → Overweight 2026-11-03 43% win rate (7 calls)
Citigroup ↑ Upgrade
Neutral → Buy 2026-11-03 Building track record
JP Morgan ↑ Upgrade
Neutral → Overweight 2026-10-07 43% win rate (7 calls)
JP Morgan - Reiterated
Neutral → Neutral 2026-06-22 43% win rate (7 calls)
JP Morgan - Reiterated
Neutral → Neutral 2026-04-30 43% win rate (7 calls)
B of A Securities ↓ Downgrade
Buy → Neutral 2026-02-24 Building track record
Morgan Stanley ↓ Downgrade
Equal-Weight → Underweight 2026-02-13 Building track record
UBS ↓ Downgrade
Buy → Neutral 2026-01-16 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
17/30
Consensus clarity
20/30
Vote unanimity
12/25
Rating stability
10/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →